8-methoxy-7,10-dimethyl-10H-benzo[g]pteridine-2,4-dione | 96323-42-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 8-methoxy-7,10-dimethyl-10H-benzo[g]pteridine-2,4-dione
• 英文别名: 8-Methoxy-7,10-dimethyl-10H-benzo[g]pteridin-2,4-dion；8-Methoxy-7,10-dimethylbenzo[g]pteridine-2,4-dione；8-methoxy-7,10-dimethylbenzo[g]pteridine-2,4-dione
• CAS: 96323-42-1
• 化学式: C₁₃H₁₂N₄O₃
• 分子量: 272.263
• InChiKey: FCVBMISOUBSDEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  83.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  8-chloro-7,10-dimethyl-10H-benzo[g]pteridine-2,4-dione 、 sodium methylate 生成 8-methoxy-7,10-dimethyl-10H-benzo[g]pteridine-2,4-dione
  参考文献：
  名称：

  Lumiflavin系列的研究V.异四恶嗪核心黄素二聚体上8位取代基的比反应性

  摘要：

  与B.＆A. Pullman的LCAO-MO模型相符，核黄素和lumiflavin的8-甲基被激活。8-氯-7,10-二甲基黄素与亲核试剂的反应，具有NO和CO基团的8-甲基黄素的反应以及8-甲基黄素的碱催化二聚产生了新的化学证据。类黄素类颜料。描述了这些“双黄素”的特定氧化还原行为，并讨论了其可能的生化重要性。

  DOI：

  10.1002/hlca.19590420645

文献信息

• NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF
  申请人：FOUNDATION MEDICINE, INC.

  公开号：US20150073036A1

  公开（公告）日：2015-03-12

  Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.
• PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY
  申请人：Technische Universitat Dresden

  公开号：US20170189522A1

  公开（公告）日：2017-07-06

  The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75 NTR , which is expressed by plasmacytoid dendritic cells. More specifically, the invention relates to a combination comprising at least one modulator of p75 NTR signalling selected from a p75 NTR antagonist or p75 NTR agonist and at least one TLR receptor agonist selected from an agonist of TLR7 and/or TLR9. The invention further relates to the use of a combination of antagonists and agonists of p75 NTR signalling and agonists of TLR7 and/or TLR9 as vaccine adjuvants and the invention provides vaccine compositions comprising antagonists and agonists of p75 NTR signalling and agonists of TLR7 and/or TLR9. The agonists and antagonists of p75 NTR signalling are useful in the manufacture of drugs for controlling cytokine function, antigen presentation, activation and proliferation of lymphocytes, which is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders, growth disorders, infections and any other conditions involving p75 NTR signal transduction. The invention provides assays to screen for a range of agonists and antagonists of p75 NTR useful in modulating cytokine function, activation and proliferation of lymphocytes. The present invention further provides, therefore, screening assays for agonists and antagonists of p75NTR-modulated immune responses.
• Studien in der Lumiflavin-Reihe V. Spezifische Reaktivität 8-ständiger Substituenten am Isoalloxazin-Kern Flavin-Dimere
  作者：P. Hemmerich、B. Prijs、H. Erlenmeyer

  DOI：10.1002/hlca.19590420645

  日期：——

  The 8-methyl group of riboflavin and lumiflavin is shown to be activated, in agreement with B. & A. Pullman's LCAO-MO-model. Chemical evidence for this is given by reactions of 8-chloro-7,10-dimethyl-flavin with nucleophilic agents, of 8-methylflavins with NO and CO groups, and by the base-catalysed dimerisation of 8-methylflavins giving rise to a new class of flavin-like pigments. The particular redox-behaviour

  与B.＆A. Pullman的LCAO-MO模型相符，核黄素和lumiflavin的8-甲基被激活。8-氯-7,10-二甲基黄素与亲核试剂的反应，具有NO和CO基团的8-甲基黄素的反应以及8-甲基黄素的碱催化二聚产生了新的化学证据。类黄素类颜料。描述了这些“双黄素”的特定氧化还原行为，并讨论了其可能的生化重要性。